The collaboration between the International Center for Genetic Disease and the Department of Health in Abu Dhabi is making significant strides in precision medicine for the Emirati population. This partnership focuses on three key areas: clinical and translational research, capacity building and technology transfer, and commercialization. The goal is to tailor the prevention, diagnosis, and treatment of diseases using cutting-edge precision medicine approaches. Recently, the International Center for Genetic Disease, affiliated with Brigham and Women’s Hospital and Harvard Medical School, launched a six-month program to train 100 physicians in the United Arab Emirates in clinical genomic medicine and genetic counseling. The initiative, in collaboration with the Department of Health in Abu Dhabi and Khalifa University of Science and Technology, aims to enhance global genomic capabilities and improve healthcare outcomes.

Genomic medicine, also known as precision medicine, is a transformative approach that uses an individual’s genetic profile to personalize their healthcare journey. The program, led by experts from the Mass General Brigham system and Harvard-affiliated institutions, will equip Emirati physicians with the knowledge and skills to address genetic challenges in a clinical setting. This comprehensive partnership not only advances life sciences but also brings precision medicine to the forefront of public health policy in the UAE. The training program aligns with the Emirati Genome Program, emphasizing screening, diagnosis, and treatment of genetic conditions. The ultimate goal is to integrate genetics and genomics into patient care effectively, improving the overall well-being of the UAE population. The inaugural ceremony, attended by key Emirati officials, underscores the commitment to enhancing healthcare and solidifying Abu Dhabi’s position as a leading destination for healthcare innovation.